University of Colorado

J-pharma Co., Ltd.

Eastman Chemical Company

University of Virginia Patent Foundation

Indiana University

Other

National Jewish Health

Michael Fitzpatrick Wempe

David B Ross

Dan Theodorescu

Phillip Reigan

Chao Yan

Samy O Meroueh

Martin A Schwartz

Hitoshi Endou

David T Ross

Liu Deng

Neil Warren Boaz

Stephanie Kay Clendennen

Philip Reigan

Jeffrey Michael Clauson

Isao Okayasu

Johan L Van Hove

Naohiko Anzai

Curtis Coughlin, Ii

Andres Vazquez-torres

Shaodong Dai

Jean-Francois Peyron

Junji Furuse

Promsuk Jutabha

David Ross

O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-L-tyrosine or a pharmacologically acceptable salt thereof exhibits high therapeutic effects on bile duct cancer, colorectal cancer, esophageal cancer, breast cancer, and pancreatic cancer.

Cancer therapeutic

The present invention relates to the discovery of novel N-(substituted)-1H-1,2,4-triazole-3-carboxamide compounds capable of inhibiting DksA activity in a bacteria cell. In certain embodiments, the compounds are capable of killing or weakening bacteria. In another aspect, the invention relates to methods of treating bacterial infection in a subject in need thereof, the method comprising administering to the subject a compound of the invention.

N-substituted-1H-1,2,4-triazole-3-carboxamides, analogues thereof, and methods of treatment using same

Methods for determining the presence or amount of oxopiperidine in a biological sample using mass spectrometry. These methods may be used to efficiently and non-invasively diagnose pyridoxine dependent epilepsy (PDE) due to deficient a-aminoadipic-δ-semialdehyde (α-AASA) dehydrogenase activity due to mutations in ALDH7A1, resulting in the accumulation of Δ-P6C, P6CH, and 6-Oxo-PIP in biological samples.

6-oxo-pipecolic acid quantitation by mass spectrometry

The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.

Anti-cancer compounds targeting Ral GTPases and methods of using the same

Methods of inhibiting the growth or metastasis of a cancer in a subject by inhibiting a Ral GTPase in the subject, and small molecule inhibitors of Ral GTPases useful in the methods of the invention. Pharmaceutical compositions containing the compounds of the invention, and methods of using the same.

Anti-cancer compounds targeting ral GTPases and methods of using the same

A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

Anticancer agent composition

A compound represented by the general Formula I: 

Developing potent urate transporter inhibitors: compounds designed for their uricosuric action

Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids were prepared chemically and/or enzymatically. Depending upon the ester, improved melanocyte cytotoxicity was achieved. Improved cytotoxicity characteristics are consistent with ester analogs being more physiologically compatible and less irritating to skin than their corresponding acids.

Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof

Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H-pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions.

5-hydroxy-2-methyl-4H-pyran-4-one esters as novel tyrosinase inhibitors

Growing community of inventors

Aurora, CO, United States of America

Michael Fitzpatrick Wempe